Precipio Launches its Proprietary HemeScreen™ AML (Acute Myeloid Leukemia) Molecular Panel
22 sept. 2020 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced today that it has launched its HemeScreen™ AML (Acute Myeloid...
Precipio Announces a Shareholder Call to Discuss its COVID-19 Progress and Future Plans
04 sept. 2020 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting a shareholder call to address questions related to the...
Precipio & ADS Biotec Sign Global Distribution Agreement for IV-Cell™
20 août 2020 13h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has signed an exclusive global distribution agreement with ADS...
Precipio Announces Q2-2020 Corporate Update Call For Shareholders
07 août 2020 09h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q2-2020 corporate update call on Monday, August 17th at...
Precipio Launches Covid-19 Antibody Test in its CLIA laboratory
04 août 2020 10h45 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced it has completed the internal validation of the FDA-approved COVID-19...
Precipio Announces Commercial Launch of COVID-19 Antibody Test
30 juil. 2020 10h15 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 30, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), is announcing its COVID-19 strategy, and its intent to contribute to the battle...
Precipio Announces Q2-2020 Unaudited Pathology Services Revenue Increased Approximately 50% over Q1’20
22 juil. 2020 10h15 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced its preliminary unaudited revenues for its pathology services increased...
Precipio Regains Listing Compliance with NASDAQ Minimum Bid Requirement
01 juil. 2020 14h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 01, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that it has regained compliance with the Nasdaq listing requirements. On...
Precipio Adds Another HemeScreen™ Customer
09 juin 2020 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., June 09, 2020 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO), announced that Cancer and Hematology Centers of Western Michigan (CHCWM) has adopted...
Q1-2020 Net Revenues increase 77% over Q4-2019 to $1.2M
15 mai 2020 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), filed its form 10Q for the period ending March 31st, 2020. Within the report,...